BioSpace News Archive

Coeptis Therapeutics Holdings, Inc. announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. (“Deverra Therapeutics”) pursuant to which it has obtained an exclusive right, until August 31, 2023.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 2, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 second quarter ended March 31, 2023.

CureVac N.V. will report financial results, and provide business updates for the fourth quarter and full-year 2022 on Tuesday, April 25, 2023.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, a service of Intermountain Health, are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today presented promising clinical data from its Phase 1/2a first-in-human study of its DNA-based personalized cancer immunotherapy, EVX-02 in combination with the checkpoint inhibitor nivolumab.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 2, 2023 to report its first quarter 2023 financial results and provide a corporate update.

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, attended the 2023 Emerging Topic Conference on NASH Cirrhosis: From Mechanisms to Management, sponsored by the American Association for the Study of Liver Diseases (AASLD)

Femasys Inc. (NASDAQ: FEMY) today announced the Health Canada, the Public Health Agency of Canada, has granted product approval of FemaSeed®, the first-ever infertility solution designed to deliver sperm directly to where contraception occurs.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an update of results from the final multiple-dose cohort in the ongoing Phase 1a study of its investigational next-generation, highly potent hepatitis B virus (HBV) core inhibitor, ABI-4334.

HTG Molecular Diagnostics, Inc., a platform-based life science tools and drug discovery company, announced the achievement of three significant drug discovery business milestones in the first quarter of 2023.